通过调节STAT3信号通路来对抗癌症白内障,聚达丁的治疗潜力
Phuong T Ho1, Nalae Kang2, Quynh Xuan Thi Luong3
1Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Nutrients
|February 27, 2026
概括
聚达丁是一种天然化合物,通过减少肌肉损失和炎症,有效地对抗癌症缓解症. 它通过抑制INTERLEUKIN-6/STAT3信号通路来起作用,为这种衰弱的疾病提供了潜在的新疗法.
科学领域:
- 生物化学 生物化学
- 药理学 药理学 是一个学科.
- 在瘤学瘤学.
背景情况:
- 癌症焦虑症是一种严重的消耗综合征,在晚期癌症患者中,其特征是显著的体重和肌肉质量损失.
- 目前癌症缓冲症的治疗方法有限,这突出了需要新的治疗策略.
- 了解肌肉缩的潜在机制对于开发有效干预措施至关重要.
研究的目的:
- 评估天然化合物聚达丁在癌症缓解症的临床前模型中的治疗潜力.
- 研究聚达丁改善肌肉缩的分子机制,重点关注IL6/STAT3信号通路.
主要方法:
- 使用携带CT26的小鼠进行体内研究,以评估聚达丁对体重,肌肉质量和炎症的影响.
- 用C2C12髓细胞进行体外实验,以分析聚达丁对由癌症条件介质诱导的肌肉缩的影响.
- 分子对接模拟用于预测IL6/STAT3通路中的聚达丁和关键蛋白之间的相互作用.
主要成果:
- 聚达丁治疗 (100毫克/公斤) 显著逆转体重减轻,肌肉缩和炎症在癌症缓解症模型小鼠.
- 聚达丁的使用减轻了肌肉纤维的收缩,使E3泛素酶 (MuRF1,Atrogin-1) 的表达正常化,并降低了互白素-6水平.
- 在体外,聚达丁改善了肌肉缩,并在C2C12神经管中抑制了STAT3酸化.
结论:
- 聚达丁在减轻与癌症缓解症相关的肌肉缩方面表现出显著的治疗疗效.
- 该机制涉及对STAT3信号通路的抑制,这表明聚达丁是癌症缓解症药物开发的有希望的候选者.
相关概念视频
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
The JAK-STAT Signaling Pathway
13.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.4K
PI3K/mTOR/AKT Signaling Pathway
5.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.9K
Receptor Downregulation in MVBs
2.9K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.9K
Drugs that Stabilize Microtubules
2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
